Cytoreductive surgery for ovarian cancer

Surgical Clinics of North America

Volumn 81, Issue 4, 2001, Pages 871-883

  Randall, Thomas C ^b   Rubin, Stephen C ^b  

^a PENNSYLVANIA HOSPITAL   (United States)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

CISPLATIN; CYCLOPHOSPHAMIDE; PACLITAXEL; PLATINUM;

ADVANCED CANCER; CANCER SURGERY; CANCER SURVIVAL; FEMALE; HUMAN; OVARY CANCER; PRIORITY JOURNAL; REVIEW; SURGICAL ANATOMY; SURGICAL TECHNIQUE; TUMOR VOLUME;

EID: 0035194403     PISSN: 00396109     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0039-6109(05)70171-7     Document Type: Article

References (48)

1. Debulking surgery: Does it increase the quality of survival?
2. Survival impact of surgical cytoreduction in stage IV epithelial ovarian cancer
3. Cisplatin methotrexate and 5-fluorouracil combination chemotherapy for advanced ovarian cancer
4. Stage IV ovarian cancer: Impact of surgical debulking
5. Stage III epithelial ovarian cancer: The role of maximal surgical resection
6. The impact of subspecialty training on the management of advanced ovarian cancer
7. A mathematic model for relating the drug sensitivity of tumors to their spontaneous mutation rate
8. The role of cytoreductive surgery in the management of stage IV epithelial ovarian carcinoma
9. Surgical resection of tumor bulk in the primary treatment of ovarian carcinoma
10. Success and failure in the treatment of solid tumors: I. Effects of cyclophosphamide (NSC-26271) on primary and metastatic plasmacytoma in the hamster
11. Epithelial ovarian carcinoma: Principles of primary surgery
12. The influence of cytoreductive surgery on progression-free interval and survival in epithelial ovarian cancer
13. The influence of cytoreductive surgery on recurrence-free interval and survival in small-volume stage III epithelial ovarian cancer: A Gynecologic Oncology Group study
14. Influence of secondary cytoreduction at the time of second-look laparotomy on the survival of patients with epithelial ovarian carcinoma
15. Neoadjuvant chemotherapy and interval debulking for advanced epithelial ovarian cancer
16. The behavior of serous tumors of low malignant potential: Are they ever malignant?
17. Cancer statistics
18. A randomized trial comparing whole abdominal radiotherapy with chemotherapy following cisplatinum cytoreduction in epithelial ovarian cancer
19. Second-look laparotomy in epithelial ovarian carcinoma: Prognostic factors associated with survival duration
20. Effect of surgical debulking on survival in stage IV ovarian cancer
21. Secondary cytoreductive surgery in epithelial ovarian cancer: Nonresponders to first-line therapy
22. Secondary cytoreductive surgery for recurrent epithelial ovarian cancer
23. Prognostic significance of residual disease in patients with stage IV epithelial ovarian cancer
24. The changing prognosis and treatment in cancer of the ovary: A report of 235 patients with primary ovarian carcinoma 1952-1961
25. Optimal cytoreductive surgery is an independent prognostic indicator in stage IV epithelial ovarian cancer with hepatic metastases
26. Cytoreductive surgery with or without preceding chemotherapy in ovarian cancer
27. Preoperative abdominopelvic computed tomographic prediction of optimal cytoreduction in epithelial ovarian carcinoma
28. Tumor size sensitivity to therapy, and design of treatment schedules
29. Randomized trial of cyclophosphamide plus cisplatin with or without doxorubicin in ovarian carcinoma: A Gynecologic Oncology Group Study
30. Randomized phase II trial of cisplatin/paclitaxel versus carboplatin/paclitaxel in optimal stage III epithelial ovarian cancer: A Gynecologic Oncology Group Trial (GOG 158)
31. Evaluation of treatment and survival after positive second-look laparotomy
32. Prognostic parameters in patients with advanced ovarian malignant tumors
33. A second-look laparotomy
34. Intervention debulking surgery in advanced epithelial ovarian cancer
35. Neoadjuvant chemotherapy for advanced ovarian cancer
36. Histological typing of female genital tract tumours
37. Secondary cytoreduction for ovarian cancer following cisplatin therapy
38. Outcome of primary cytoreduction surgery for advanced epithelial ovarian cancer
39. Ten year follow-up of patients receiving cisplatin doxorubicin, and cyclophosphamide chemotherapy for advanced epithelial ovarian carcinoma
40. Managment of epithelial ovarian tumors of low malignant potential
41. The effect of debulking surgery after induction chemotherapy on the prognosis in advanced epithelial ovarian cancer
42. Morbidity and mortality associated with primary and repeat operations for ovarian cancer
43. Cisplatin based combination chemotherapy for advanced ovarian cancer: High overall response rate with curative potential only in women with small tumor borders
44. The role of secondary cytoreductive surgery in epithelial ovarian malignancies
45. Secondary cytoreductive surgery at second-look laparotomy in advanced ovarian cancer: A gynecologic oncology group study
46. Primary or delayed debulking surgery and chemotherapy consisting of cisplatin, doxorubicin, and cyclophosphamide in stage III-IV epithelial ovarian carcinoma